Cellectar Biosciences (CLRB) announced the signing of a multi-year supply agreement in which Nusano will provide Cellectar with iodine-12 and actinium-225 for its clinical studies and future commercial needs. “Securing a reliable supply of both iodine-125 and actinium-225 is a critical milestone in advancing our targeted radiotherapy programs,” said James Caruso, chief executive officer of Cellectar. “This agreement ensures uninterrupted access to these essential isotopes, providing the necessary clinical development supply for our innovative clinical stage programs, including CLR 125 for triple negative breast cancer and CLR 225 for pancreatic cancer. We look forward to partnering with Nusano to support our mutual vision to deliver new radiotherapeutics to patients in critical need of novel treatment options. I-125 and Ac-225 will be produced at Nusano’s next-generation radioisotope production facility in Utah. This production platform enables the creation of rare and hard-to-produce medical radioisotopes in quantities needed for commercial-stage therapeutics and diagnostics.”
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLRB:
- Cellectar submits a protocol with U.S. FDA for Phase 1b Dose Finding study
- Cellectar Biosciences trading halted, news pending
- Upcoming Stock Splits This Week (June 23 to June 27) – Stay Invested
- Cellectar Biosciences Announces Reverse Stock Split
- Cellectar Biosciences announces 1-for-30 reverse stock split